← Back to all media
Covid-driven biotech and healthcare run set to continue for investors with high risk tolerance
The biotech and healthcare sectors have flourished during the pandemic as companies raced to develop a Covid-19 vaccine. Those already invested have reaped the rewards, but what next? Is it time to reconsider this exposure or is there more to come?
Published on 3rd August 2021